Will the EU still have Big Pharma’s back abroad?

…Like a lot of people in trade, I always thought the WTO waiver talks were a bit of a sideshow, but one good outcome would have been a warning to the pharma industry that their home governments didn’t automatically have their back, plus sending a general signal about the need for IP policy space during medical emergencies. If the EU wants to show a bit of spine and lean on its drugs companies to ease off lobbying against CLs abroad, this would be a good opening to do it…